" class="no-js "lang="en-US"> Tempero Bio Advance Treatment of Alcohol & Substance Disorders
Friday, February 03, 2023

Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders

Sosei Group Corporation, the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, notes its partner Tempero Bio has announced FDA clearance of its Investigational New Drug (IND) application for TMP-301 (formerly HTL0014242) for the treatment of alcohol and substance use disorders.

Tempero Bio is planning to initiate a Phase 1 study with TMP-301 in healthy volunteers in Q1 2023 with support from a recently awarded USD$5.3M grant from the US National Institute on Drug Abuse (NIDA). The full announcement from Tempero Bio is here.

Matt Barnes, Head of UK R&D, Sosei Heptares, commented: “We would like to congratulate the team at Tempero Bio on reaching this important milestone. We look forward to further clinical development progress from Tempero Bio with TMP-301 and its mGluR5 NAM pipeline as it seeks to develop effective treatments for patients with serious substance and alcohol use disorders.”

Tempero Bio was created in 2020 by the venture firm Aditum Bio (established by industry veterans Joe Jimenez and Mark Fishman) in collaboration with Sosei Heptares to advance the clinical development of a portfolio of potent, orally available metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) modulators, including TMP-301, discovered by Sosei Heptares to develop therapies targeting substance use disorders and anxiety.

Under the terms of the agreement, Tempero Bio acquired exclusive global rights to Sosei Heptares’ portfolio of mGluR5 NAM candidates. In return, Sosei Heptares received a strategic equity stake in Tempero Bio and is eligible to receive future success-based development and commercial milestone payments plus tiered royalties from any future product sales. The regulatory milestone achieved as noted in this announcement does not trigger a payment from Tempero Bio to Sosei Heptares.

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more